128 related articles for article (PubMed ID: 30038713)
1. A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.
Cheriyan VT; Alsaab H; Sekhar S; Venkatesh J; Mondal A; Vhora I; Sau S; Muthu M; Polin LA; Levi E; Bepler G; Iyer AK; Singh M; Rishi AK
Oncotarget; 2018 Jul; 9(51):29680-29697. PubMed ID: 30038713
[TBL] [Abstract][Full Text] [Related]
2. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
3. Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers.
Muthu M; Somagoni J; Cheriyan VT; Munie S; Levi E; Ashour AE; Yassin AE; Alafeefy AM; Sochacki P; Polin LA; Reddy KB; Larsen SD; Singh M; Rishi AK
J Biomed Nanotechnol; 2015 Sep; 11(9):1608-27. PubMed ID: 26485930
[TBL] [Abstract][Full Text] [Related]
4. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.
Cheriyan VT; Alsaab HO; Sekhar S; Stieber C; Kesharwani P; Sau S; Muthu M; Polin LA; Levi E; Iyer AK; Rishi AK
Oncotarget; 2017 Dec; 8(62):104928-104945. PubMed ID: 29285223
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
Surapaneni SK; Nottingham E; Mondal A; Patel N; Arthur P; Gebeyehu A; Kalvala AK; Rishi AK; Singh M
Anticancer Res; 2021 Sep; 41(9):4215-4228. PubMed ID: 34475041
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
7. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
8. Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts.
Nimma R; Kalvala AK; Patel N; Surapaneni SK; Sun L; Singh R; Nottingham E; Bagde A; Kommineni N; Arthur P; Nathani A; Meckes DG; Singh M
Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745729
[TBL] [Abstract][Full Text] [Related]
9. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
10. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
13. CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis.
Muthu M; Cheriyan VT; Rishi AK
Oncotarget; 2015 Mar; 6(9):6499-510. PubMed ID: 25894788
[TBL] [Abstract][Full Text] [Related]
14. β-elemene enhances the antitumor activity of erlotinib by inducing apoptosis through AMPK and MAPK pathways in TKI-resistant H1975 lung cancer cells.
Wang J; Xu C; Chen Y; Shao L; Li T; Fan X; Yu L; Zhang R; Chen B; Chen H; Sui X; Leung EL; Wu Q
J Cancer; 2021; 12(8):2285-2294. PubMed ID: 33758606
[TBL] [Abstract][Full Text] [Related]
15. Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.
Xu ZH; Shun WW; Hang JB; Gao BL; Hu JA
Tumour Biol; 2015 Jul; 36(7):5485-95. PubMed ID: 26036758
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
17. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
20. Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.
Furugaki K; Iwai T; Moriya Y; Harada N; Fujimoto-Ouchi K
Lung Cancer; 2014 Jan; 83(1):44-50. PubMed ID: 24192512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
